HPV HIGH RISK

Why get tested?
This test is indicated for the early screening of cervical cancer and for the detection of persistent genital infections caused by high-risk oncogenic human papillomavirus (HPV). Types 16 and 18 alone account for approximately 70% of cervical cancers.

What test see?
The test detects the presence of DNA from 14 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), providing specific typing of the strains associated with the highest risk.

What test see?
Persistent infections caused by high-risk HPV strains are the leading cause of precancerous lesions and cervical cancer. Early detection of the virus allows for the scheduling of gynecological checkups or second-level diagnostic tests (colposcopy/cytology).


How is the test administered on?
The test is performed on a sample of cells from the cervix (collected via traditional cytology or ThinPrep® liquid-based cytology). Analysis of the 14 high-risk genotypes is conducted using the automated BD Onclarity method.

Turnaround Times
Results in 8 working days.

Turnaround Times
Clinical sensitivity and specificity > 98.6% (Analytical specificity > 99%)